PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of halLink to Publisher's site
 
Nat Cell Biol. Author manuscript; available in PMC 2008 May 23.
Published in final edited form as:
PMCID: PMC2394707
HALMS: HALMS145547
INSERM Subrepository

Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2

Abstract

Aberrant constitutive expression of c-Rel, p65 and p50 NF-κB subunits has been reported in over 90% of breast cancers1,2. Recently, we characterized a de novo RelB NF-κB subunit synthesis pathway, induced by the cytomegalovirus (CMV) IE1 protein, in which binding of p50/p65 NF-κB and c-Jun/Fra-2 AP-1 complexes to the RELB promoter work in synergy to potently activate transcription3. While RelB complexes were observed in mouse mammary tumors induced by either ectopic c-Rel expression4 or carcinogen exposure5, little is known about RelB in human breast disease. Here, we demonstrate constitutive de novo RelB synthesis is selectively active in invasive estrogen receptor (ER)α negative breast cancer cells. ERα signaling reduced levels of functional NF-κB and Fra-2 AP-1 and inhibited de novo RelB synthesis, leading to an inverse correlation between RELB and ERα gene expression in human breast cancer tissues and cell lines. Induction of Bcl-2 by RelB promoted the more invasive phenotype of ERα negative cancer cells. Thus, inhibition of de novo RelB synthesis represents a new mechanism whereby ERα controls epithelial to mesenchymal transition (EMT).

Keywords: Animals, Blotting, Northern, Breast Neoplasms, genetics, metabolism, pathology, Cell Line, Tumor, Cell Movement, genetics, physiology, Cell Transformation, Neoplastic, genetics, Electrophoretic Mobility Shift Assay, Estrogen Receptor alpha, genetics, metabolism, physiology, Estrogens, physiology, Female, Fos-Related Antigen-2, genetics, metabolism, Gene Expression Regulation, Neoplastic, Humans, Immunoblotting, Mice, Microscopy, Fluorescence, NF-kappa B, genetics, metabolism, Phenotype, Protein Binding, Proto-Oncogene Proteins c-bcl-2, genetics, metabolism, Reverse Transcriptase Polymerase Chain Reaction, Signal Transduction, physiology, Transcription Factor RelB, genetics, metabolism

To begin to assess the involvement of RelB in breast cancer, we selected the ZR-75, MCF-7, and T47D ERα positive, and Hs578T and MDA-MB-231 ERα negative human breast cancer cells, and the low expresser NF639 mouse mammary tumor line. Immunoblot analysis of whole cell protein extracts (WCEs) confirmed the expected profile of ERα (Fig. 1a, upper panel). Abundant levels of RelB protein were seen in Hs578T and MDA-MB-231 cells, while RelB was extremely low in ZR-75, MCF-7 and T47D cells; NF639 cells had an intermediate level (Fig. 1a, upper panel). Total levels of RelB and ERα proteins were found to display an inverse relationship (Fig. 1b). The difference in RelB expression in the cell lines was even more striking when the nuclear compartment was examined (Fig. 1a and b, lower panels).

Figure 1
RelB levels are inversely correlated with ERα status in breast cancer cells. (a)

Levels of RELB mRNA were also much higher in ERα negative vs positive breast cancer cells (Fig. 1c). To test whether an inverse correlation similarly exists in primary human breast cancers, a microarray gene expression dataset obtained from 295 patients6 and publicly available at Oncomine.org was analyzed. The levels of RELB mRNA were significantly higher in ERα negative vs ERα positive breast cancers (Fig. 1d) (p-value = 3.9 e−11 by Student t-test), consistent with the cell line data. Analysis of microarray datasets from three other studies confirmed this inverse correlation, including one7 with similar numbers of patient samples (p-value is 2.7 e−7). Thus, RELB mRNA levels correlate inversely with ERα status in primary human breast cancers.

In de novo RelB synthesis mediated by the CMV IE1 protein, induction of binding of active c-Jun/Fra-2 AP-1 and p50/p65 NF-κB complexes to one distal AP-1 and two proximal κB elements, respectively, was shown to synergistically activate the RELB promoter in NIH 3T3 and smooth muscle cells3; whereas, c-Jun/c-Fos AP-1 was inactive. EMSA showed that ERα negative or low cells displayed much higher basal levels of AP-1 and NF-κB binding compared to the ERα positive lines, as previously reported1,8 (Fig. 1e). Immunoblot analysis detected higher nuclear levels of Fra-2, c-Jun, and Fra-1 in ERα negative or low vs ERα positive cells; whereas JunB, and to a lesser extent JunD and c-Fos, were elevated in ERα positive cells (Fig. 1f).

To test for de novo RelB synthesis, transfection analysis was performed with the RELB promoter and vectors expressing various AP-1 subunits in Hs578T cells, which display constitutive p50/p65 NF-κB activity9. Ectopic expression of c-Jun or Fra-2 alone led to an approximate 6- or 3-fold activation of RELB promoter, respectively (Fig. 2a), while the combination induced RELB promoter activity by ~26-fold (Fig. 2a). Similar synergy was seen in MDA-MB-231 and NF639 cells, whereas only an additive effect on RELB promoter activity was seen in the three ERα positive cells (Fig. 2b). Expression of c-Fos alone or in combination with c-Jun was unable to substantially induce RELB promoter activity. Somewhat surprisingly Fra-1, which was moderately active in NIH 3T3 cells3, failed to induce RELB promoter activity (Fig. 2a).

Figure 2Figure 2
c-Jun/Fra-2 AP-1 and p50/p65 NF-κB complexes synergistically induce RELB promoter activity in ERα negative breast cancer cells

To test whether the synergy seen was indeed due to the high endogenous NF-κB activity in ERα negative cells, the NF-κB inhibitory protein IκB-α was co-expressed in Hs578T and MCF-7 cells. IκB-α expression strongly blocked the synergy between c-Jun and Fra-2 in Hs578T cells, while having little effect in MCF-7 cells or on c-Jun and Fra-2 alone (Fig. 2c). When a RELB promoter construct with mutation of the κB elements was analyzed, the co-expression of c-Jun and Fra-2 led to activation that was only additive in ERα negative cells (Fig. 2d), confirming the role of NF-κB in the observed synergy.

To test directly the roles of c-Jun and Fra-2 in MDA-MB-231 and Hs578T cells, si-JUN or si-FRA2 was used, which successfully reduced endogenous c-Jun and Fra-2 levels when added alone or in combination (Fig. 2e). Knockdown of c-Jun alone had little effect on RelB expression in MDA-MB-231, but substantially decreased RelB levels in Hs578T cells. An ~30–40% reduction in RelB levels was seen in both lines upon knockdown of Fra-2 alone. When both AP-1 subunits were reduced, an ~50–90% decrease in RelB levels occurred (Fig. 2e), confirming the role of c-Jun/Fra-2 heterodimers in activation of endogenous RelB. Lastly, the ability of c-Jun/Fra-2 and p50/p65 to act in synergy was tested directly using reduced suboptimal doses of each expression vector. A potent induction of the RELB promoter activity was observed in both ERα negative and positive cells (Fig. 2f). In contrast, Fra-2 and JunB, which are highly expressed in ERα positive cells, were unable to induce RELB promoter activity (data not shown). Thus, c-Jun/Fra-2 AP-1 and p50/p65 NF-κB complexes, which are highly expressed in ERα negative or ERα low breast cancer cells, work in synergy to induce de novo RelB synthesis.

To assess the role of ERα in de novo RelB synthesis, MCF-7 and T47D cells were treated with the anti-estrogen ICI 182,780, which inhibits estrogen-dependent ERα function10 and decreases ERα protein levels11 (Fig. 3a). ICI 182,780 treatment increased RelB protein and RNA levels (Fig. 3a), and induced both NF-κB and AP-1 DNA binding and activity (Figs. 3b, 3c, Supplementary Information, Fig. S1a1–a4). Similarly, siRNA-induced knockdown of ERα substantially increased RelB levels in MCF-7 cells (Fig. 3d).

Figure 3Figure 3
ERα represses NF-κB and AP-1 activities and reduces RelB levels

The effects of ectopic ERα expression were assessed in MDA-MB-231 and Hs578T cells in the presence of 17β-estradiol (E2). Activation of ERα signaling substantially decreased RelB protein levels in MDA-MB-231 (61.8%) and Hs578T (47.4%) cells (Fig. 3e). To test the effects of active ERα on de novo RelB synthesis, RELB promoter constructs were used in MDA-MB-231 cells. Mutation of either the κB or AP-1 site partially reduced basal promoter activity, and the double mutation resulted in an ~90% reduction, confirming the roles of the two factors in control of RELB promoter transcription. Ectopic ERα signaling resulted in strong repression of the WT RELB promoter, but only partial or no inhibition of the promoters with mutations in either the κB or AP-1 site, or with a double mutation, respectively was seen (Fig. 3f). Thus, ERα signaling effectively represses RELB promoter activity driven by NF-κB and AP-1.

While the mechanisms mediating repression of NF-κB by ERα have been extensively studied12, little is known about how ERα represses AP-1. We noted that ERα negative cells have higher levels of Fra-2 compared to positive ones, which led us to hypothesize that ERα signaling represses Fra-2 expression, and thereby AP-1 activity. Consistent with this hypothesis, inhibition of ERα in MCF-7 cells led to an increase in Fra-2 levels, while c-Jun was unaffected (Fig. 3g). Conversely, ectopic ERα signaling in MDA-MB-231 or Hs578T cells decreased Fra-2 expression (Fig. 3h). Knockdown of ERα in MCF-7 cells led to an increase in Fra-2 at day 1, which preceded the increase in RelB levels that were noted after 2 days (Fig. 3i). Similarly, induction of ERα signaling in MDA-MB-231 decreased Fra-2 levels after 1 day, preceding the decrease in RelB levels detectable after day 2 (Fig. 3j). Thus, repression of Fra-2 by ERα plays a substantial role in inhibition of de novo RelB synthesis.

Highly invasive and metastatic breast cancers are frequently ERα negative1315. To test the role of RelB in invasive phenotype, Hs578T cells with knockdown of RelB (Hs578T/si-RELB) or control sense RelB cells (Hs578T/si-Control) were prepared (Fig. 4). Expression of Snail, the repressor of E-cadherin gene (CDH1) transcription, was decreased in Hs578T/si-RELB cells at both the mRNA and protein level (Figs. 4a, 4b). Furthermore, levels of the epithelial markers E-cadherin and γ-catenin were increased in Hs578T/si-RELB cells (Fig. 4b). A substantial decrease in fibronectin protein expression, a mesenchymal marker, was also observed. Importantly, Hs578T/si-RELB cells displayed decreased motility (Fig. 4c), and ability to form invasive colonies in Matrigel (Fig. 4d). Thus, RelB expression is required for maintenance of mesenchymal phenotype of ERα negative Hs578T breast cancer cells.

Figure 4
RelB expression promotes mesenchymal phenotype of breast cancer cells

To determine whether ectopic expression of RelB can promote a more mesenchymal phenotype in ERα positive breast cancer cells, MCF-7 were transfected with pcDNA3-RELB expression vector or parental pcDNA3 EV DNA (MCF-7/RELB and MCF-7/EV, respectively), and several independent stable clones (MCF-7/RELB) expressing elevated RelB levels isolated (Fig. 4e–h). RelB overexpression was sufficient to lead to a marked decrease in E-cadherin levels (Fig. 4e, and see immunofluorescence in Supplementary Information, Fig. S3). RelB also increased levels of fibronectin, and vimentin, another mesenchymal marker (Fig. 4e). Stable RelB overexpression resulted in a more than 5-fold increase in migration of MCF-7 cells (Fig. 4f), enhanced cell scattering (Fig. 4g), and increased invasion through Matrigel [1.7-fold; 0.43 ±0.08 vs 0.25 ±0.06]. RelB overexpression also led to increased colony size in Matrigel (Fig. 4h); although, it was insufficient to allow for branching colony formation. Lastly, induction of RelB led to a more invasive gene profile within 48 h (Fig. 4i), and to a 4.7-fold increase in migration (not shown). Thus, RelB expression in ERα positive breast cancer cells decreases epithelial and increases mesenchymal characteristics.

To further monitor the oncogenic effects of RelB expression, cells were subjected to irradiation and RelB was found to greatly promote resistance to killing (X.W., K.B., H. Ying, Z.X. Xiao, G.E.S., manuscript in preparation). This led us to examine the effects of RelB on expression of the pro-survival Bcl-2 protein, product of an NF-κB p50/RelA target gene16. Inhibition of RelB led to a decrease in Bcl-2 protein levels in Hs578T cells, while ectopic RelB induced its expression in MCF-7 cells (Fig. 5a, upper panels). Consistently, endogenous Bcl-2 levels were higher in the ERα negative Hs578T and MDA-MB-231 lines compared to ERα positive ZR-75 and MCF-7 cells (Fig. 5b). To begin to test for transcriptional activation of the BCL2 gene by RelB, we first confirmed that RelB levels controlled BCL2 mRNA expression (Fig. 5a, lower panels). The BCL2 gene has a TATA-less major P1 promoter, responsible for 95% of BCL2 gene transcription, and a minor P2 promoter20. In Hs578T cells, co-transfection of the WT BCL2 P1 reporter construct with the si-RELB vector, led to an ~5-fold decrease in its activity compared to the sense control (Fig. 5c). Furthermore, the activity of the WT BCL2 P1 promoter was potently induced upon co-transfection of vectors expressing RelB and p52 in either Hs578T cells (Fig 5d) or ZR-75 cells (see Supplementary Information, Fig. S2c). Induction of P1 promoter activity by NF-κB in B cells has been shown to be mediated indirectly via protein-protein interaction with CREB, which is bound to a cyclic AMP response element (CRE) at bp −1535 to −155217. When the CRE mutant and WT constructs were compared, the activity of the mutant BCL2 construct in Hs578T cells expressing the si-control vector was significantly lower (Fig. 5c), and was unable to be substantially activated upon ectopic expression of RelB/p52 in either Hs578T cells (Fig 5d) or ZR-75 cells (see Supplementary Information, Fig. S2c). Thus, RelB regulates BCL2 promoter activity in breast cancer cells.

Figure 5Figure 5
Bcl-2 mediates control of invasive properties of breast cancer cells

Recent evidence has correlated enhanced Bcl-2 levels with progression to a metastatic phenotype in prostate cancer18, leading us to hypothesize Bcl-2 mediates the effects of RelB. Ectopic Bcl-2 expression in MCF-7 and ZR-75 cells substantially decreased expression of E-cadherin and γ-catenin, while levels of the upstream regulator RelB were unaffected; migration of MCF-7 cells was enhanced (Figs. 5e, 5f). We then tested the ability of ectopic Bcl-2 to reverse the effects of inhibition of RelB in Hs578T cells. Ectopic Bcl-2 decreased expression of E-cadherin and γ-catenin, and essentially restored the ability of Hs578T/si-RELB cells to migrate and to form colonies with invasive phenotype in Matrigel (Fig. 5g–i). Lastly, knockdown of Bcl-2 decreased the ability of the Hs578T cells to form invasive colonies and to migrate (Fig. 5j–k), in association with increased E-cadherin and γ-catenin (Fig. 5l). Together, the data argue that Bcl-2 is a critical mediator of invasive properties induced by RelB.

Here, we show the ability of ERα to reduce AP-1 and NF-κB binding and activity, and thereby to suppress de novo RelB synthesis, which represents a new mechanism whereby receptor signaling maintains a more epithelial phenotype. The effects on AP-1 were mediated, in large measure, via inhibition of Fra-2. Thus, transcriptional regulatory mechanisms control RelB NF-κB activation and function. While early reports of RelB function implicated this subunit in mediating signals in the adaptive immune response19, recent studies have provided evidence for a role of RelB in cancer. We noted that several mammary tumors in MMTV-c-Rel transgenic mice expressed elevated nuclear levels of RelB4, and p52/RelB complexes were induced in mouse mammary tumors following carcinogen treatment5. p50/RelB was observed in mucosa-associated lymphoid tissue lymphomas, and these complexes inhibited apoptosis induced upon DNA damage20. RelB was the most frequently detected NF-κB subunit in the nuclei of prostate cancer tissue, correlated directly with Gleason score21, and played a radioprotective role in aggressive prostate cancer cells22. In the present study, higher levels of RelB seen in ERα negative breast cancer cell lines and human breast cancers suggest an important role for RelB in advanced breast carcinomas. Consistent with our observations, RelB was recently implicated in inflammatory breast disease23.

Huber and coworkers reported that NF-κB activity was essential for the induction and maintenance of EMT and metastasis of Ras-transformed epithelial breast cells by TGF-β124. We demonstrated that elevated NF-κB activity is critical for maintenance of EMT in a c-Rel-driven mammary tumor cell line following carcinogen treatment25. For the first time, we elucidate a critical role of RelB in EMT in breast cancer cells, and identify Bcl-2 as an important downstream mediator. RelB/p52 complexes were shown to induce BCL2 P1 promoter activity. Protection from apoptosis by such genes as BCL2 has recently been proposed to play an important role in promoting metastasis18. For example, ectopic expression of Bcl-2 in breast cancer cells increased their ability to metastasize to the lung26. Our data indicate a role for Bcl-2 in negative regulation of epithelial markers. Interestingly, Bcl-2 has recently been shown to promote the degradation of IκB-α and thereby induce NF-κB activity in cardiac myocytes27. This suggests a feed-forward mechanism, i.e., induction of Bcl-2 further enhances NF-κB activity, which promotes a mesenchymal phenotype. Experiments are in progress to test this model in breast cancer cells. ERα was previously shown to inhibit EMT via its control of MTA3 levels and repression of SNAI1 gene transcription28. Our findings indicate inhibition of de novo RelB synthesis represents an additional mechanism by which ERα can control EMT, which provides a unifying model for the observed involvement of NF-κB and AP-1 activities in EMT. Future studies exploring the role of RelB as a biomarker or in therapeutic approaches for treatment of metastatic breast disease are warranted.

METHODS

Cell culture and treatment conditions

The NF639 cell line was derived from a mammary gland tumor in an mammary tumor virus (MMTV)-ERBB2 transgenic mouse and cultured as described29. ERα positive MCF-7, T47D and ZR-75 cells, and ERα negative Hs578T and MDA-MB-231 cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA) and maintained in standard culturing medium as recommended by ATCC. Cultures were stripped of endogenous steroids by successive passages in phenol red free medium containing 10% dextran-coated charcoal (DCC)-stripped fetal bovine serum (FBS) (DCC-FBS) (2 days), and then 3% DCC-FBS (3 days)30. MCF-7 cell lines containing pcDNA3 or pcDNA3-RELB and Hs578T cell lines containing human pRELB-siRNA or control pRELB sense (si-Control) were established as described5 and grown in the presence of 400 μg ml−1 G418 (Sigma, St. Louis, MO) or 1 μg ml−1 puromycin (Sigma), respectively. MCF-7 and Hs578T/si-RELB cell lines containing pBABE and pBABE-Bcl-2 were established by retroviral infection, as described31, and used 24 h post infection. Hs578T cells carrying pSM2c-sh-BCL2 (V2HS_111806, Open Biosystems) or scrambled control were established by retroviral infection, as above. MCF-7 cells containing inducible C4bsrR(TO) or C4bsrR(TO-RelB) were established as described32. Expression of RelB was induced by treatment with 1 μg/ml doxycycline for 48 h and analyzed as described. Where indicated, cells were treated with 1 μM ICI 182,780 or equivalent volume of vehicle ethanol (Tocris Cookson, Ellisville, MO). E2 was purchased from Sigma.

Plasmids and transfection analysis

The human 1.7 kB RELB promoter driving a luciferase reporter in pGL3 basic vector (p1.7 RELB promoter-Luc) and the pcDNA3-RELB construct containing human RELB cDNA sequence in the pcDNA3 expression vector were as described previously3. The pC4bsrR(TO-RelB) construct was generated by subcloning the Relb cDNA into the Eco RI restriction site of the doxycycline inducible pC4bsrR(TO) retroviral vector. The p1.7 RELB promoter-Luc vectors containing either wild type (WT), or mutant NF-κB (κB-Mut), or AP-1 (AP1-Mut) elements alone or with the double mutation (DM) were as prepared previously3. The thymidine kinase promoter-driven luciferase reporter plasmid controlled by six reiterated κB sites, was kindly provided by G. Rawadi (Hoechst-Marion-Roussel, Romainville, France). The thymidine kinase promoter-driven chloramphenicol acetyl transferase (CAT) plasmid controlled by five copies of the TPA responsive elements (TRE), was as described previously3. The NF-κB p50 or p65 constructs in pMT2T expression vector were as reported3. The IκB-α construct containing IκB-α SS32/36AA mutant in pRC-β-actin expression vector, was as reported5. The c-Jun, c-Fos, Fra-1, and Fra-2 AP-1 family member constructs in the pCI expression vector were as reported3. pRELB sense and pRELB-siRNA containing control or si-RELB oligonucleotides in pSIREN-RetroQ vector, were described previously33. The human full-length BCL2 constructs in pcDNA3 or pBabe were as reported34. The SV40 β-galactosidase (β-gal) reporter vector was as reported3. For transfection into six well and P100 plates, 3 or 10 μg total DNA was transfected, respectively. For transient transfection, cultures were incubated for 48 h in the presence of DNA and Fugene6 (Roche Diagnostics Co., Indianapolis, IN) or Geneporter2 (Gene Therapy System Inc., San Diego, CA) Transfection Reagent. All transient transfections were performed a minimum of three times, in triplicate. For stable transfection, cells were incubated for 48 h with DNA and GenePorter2 before adding 10 μg ml−1 blasticidin, 400 μg ml−1 G418, or 1 μg ml−1 puromycin, as appropriate, for stable selection. CAT and luciferase assays were performed as described2,4. Co-transfection of the SV40-β-gal expression vector was used to normalize for transfection efficiency, as described4. Sequences of FRA2, JUN, and GFP siRNA duplexes have been previously described35. For the RelB repression studies, the ERα siRNA duplex (Dharmacon, Chicago, IL) targeted the following sequence: AAGATCCTGAAACAGAGCATG (sense strand). Transfections (100 nM final) were carried out using Oligofectamine (Invitrogen, Carlsbad, CA), in Optimem serum-free medium, 24 h after plating. When multiple transfections were performed, cells were re-plated 48 h after transfection (dilution 1:2). For kinetics studies, cell extracts were processed for immunoblotting 48 h after the last transfection. ERα validated Stealth RNAi and Stealth RNAi negative controls from Invitrogen were used. Duplexes (0.9 nM final) were introduced in cells using Lipofectamine RNAiMAX reagent (Invitrogen) by reverse transfection according to the manufacturer’s protocol. Similar results were obtained with the 2 different ERα duplexes. The BCL2 P1 promoter constructs with WT or mutant CRE sites were as described17.

Immunoblot analysis, antibodies, and immmunofluorescence

WCEs (total protein extracts) were prepared in RIPA buffer (10 mM Tris [pH 7.5], 150 mM NaCl, 10 mM EDTA, 1% NP-40, 0.1% SDS, 1% sodium sarcosyl, 0.2 mM phenylmethylsulfonylfluoride, 10 μg ml−1 leupeptin, 1 mM dithiothreitol). Nuclear extracts were prepared as previously described29. Immunoblotting was performed as we have described29. Antibodies against NF-κB members: p65 (sc-372) and RelB (sc-226), or AP-1 members: JunB (sc-46), JunD (sc-74), c-Fos (sc-7202), Fra-1 (sc-183), Fra-2 (sc-604), Bcl-2 (sc-492), or against Snail (Snail, sc-10432) or Lamin B (sc-6217), were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies against c-Jun and ERα were purchased from Cell Signaling (Danvers, MA) and NeoMarker (Fremont, CA), respectively. The E-cadherin, fibronectin, and γ-catenin antibodies were purchased from BD Transduction Lab (Franklin Lakes, NJ), and the β-actin (AC-15) and cyclin D1 (Ab-3) antibodies were from Sigma and Oncogene (Boston, MA), respectively. Immunofluorescence was performed as we have published previously25.

EMSA

Nuclear extracts were prepared and samples (5 μg) subjected to binding and EMSA as described2. The sequences of the oligonucleotide containing the consensus AP-1 element and NF-κB element upstream of the c-Myc promoter are as follows: AP-1, 5′-GATCCGCTTGATGACTCAGCCGGAAG-3′; NF-κB, 5′-GATCCAAGTCCGGGTTTTCCCCAACC-3′. The Oct-1 sequence is as reported previously2.

RT-PCR and Northern blot analysis

RNA, isolated using Trizol reagent (Invitrogen), was quantified by measuring A260. A260:A280 ratios were between 1.8 and 2. RNA samples were treated with RQ1 RNase-free DNase (Promega Corporation, Madison WI). For reverse transcriptase (RT)-PCR, 1 μg RNA was reverse transcribed with Superscript RNase H-RT in the presence of 100 ng of random primers (Invitrogen). PCR for SNAI1 was performed in a Thermal Cycler for 20 cycles as follows: 94°C for 30 sec, 55°C for 30 sec and 72°C for 30 sec, and for BCL2 for 30 cycles as follows: 94°C for 30 sec, 60°C for 30 sec and 72°C for 45 sec. The primers specific for human SNAI1 are as follows: sense (5′-GAAAGGCCTTCAACTGCAAA-3′) and antisense (5′-TGACATCTGAGTGGGTCTGG-3′. The primers specific for human BCL2 are: sense (5′-CATTTCCACGTCAACAGAATTG-3′) and antisense (5′-AGCACAGGATTGGATATTCCAT-3′). As a loading control, PCR for GAPDH was performed in a Thermal Cycler for 15 cycles: 94°C for 30 sec, 55°C for 30 sec and 72°C for 30 sec. RNA samples (20 μg) were subjected to Northern blot analysis, as described3. The 2.1-kb Eco RI inserts of the human RELB or mouse Relb cDNA expression vectors were used as probes.

Matrigel outgrowth assays

Cells (2×104) were suspended at 4°C in Matrigel (0.2 ml, 6.3 mg ml−1) (BD Biosciences, Bedford, MA), an extracellular matrix extracted from Engelbreth-Holm-Swarm mouse tumors, and added to a pre-set Matrigel layer in 24-well plates as described25. The top Matrigel cell layers were covered with culture medium containing 10% FBS.

Migration and invasion assays

Suspensions of 1 to 2.5×105 MCF-7 or Hs578T cells were layered, in triplicate, in the upper compartments of a Transwell (Costar, Cambridge, MA) on an 8-mm diameter polycarbonate filter (8 μm pore size), and incubated at 37°C for the indicated times. All migration assays were performed two to three times, in triplicate. For invasion assays, filters were precoated with 60 μg of Matrigel. Migration of the cells to the lower side of the filter was evaluated with the acid phosphatase enzymatic assay using p-nitrophenyl phosphate and OD410nm determination. The mean ± SD are presented. All invasion assays were performed two times, in triplicate.

Gene expression and statistical analysis

The Van de Vijver_Breast carcinoma microarray dataset (reporter number NM_0065096) was accessed using the ONCOMINE Cancer Profiling Database (www.oncomine.org). The dataset includes 69 ER negative and 226 ER positive human primary breast carcinoma samples. Box plots, depicting the distribution of RELB expression within each ERα group and a Student t-test giving a p-value for the comparison of RELB expression between the two ERα groups were obtained directly through the Oncomine 3.0 software. The line within the box represents the median expression value for each group, and the upper and lower edges of the box indicate the 75th and 25th percentile of the distribution, respectively. The lines (whiskers) emerging from each box extend to the smallest and largest observations; the black dots outside the ends of the whiskers are outlier data points.

Supplementary Material

Acknowledgments

We thank Finn-Eirik Johansen, Carlos V. Paya, Stanley Korsmeyer, and Linda M. Boxer for cloned DNAs, T. Akagi for the inducible retroviral vector, and P. Leder for the NF639 cell line. These studies were supported by NIH grants ES11624 and CA36355.

References

1. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ, Jr, Sledge GW., Jr Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol. 1997;17:3629–39. [PMC free article] [PubMed]
2. Sovak MA, et al. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest. 1997;100:2952–60. [PMC free article] [PubMed]
3. Wang X, Sonenshein GE. Induction of the RelB NF-kappaB subunit by the cytomegalovirus IE1 protein is mediated via Jun kinase and c-Jun/Fra-2 AP-1 complexes. J Virol. 2005;79:95–105. [PMC free article] [PubMed]
4. Romieu-Mourez R, et al. Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors. Mol Cell Biol. 2003;23:5738–54. [PMC free article] [PubMed]
5. Demicco EG, et al. RelB/p52 NF-kappaB complexes rescue an early delay in mammary gland development in transgenic mice with targeted superrepressor IkappaB-alpha expression and promote carcinogenesis of the mammary gland. Mol Cell Biol. 2005;25:10136–47. [PMC free article] [PubMed]
6. van de Vijver MJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009. [PubMed]
7. Wang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005;365:671–9. [PubMed]
8. Philips A, et al. FRA-1 expression level modulates regulation of activator protein-1 activity by estradiol in breast cancer cells. Mol Endocrinol. 1998;12:973–85. [PubMed]
9. Romieu-Mourez R, et al. Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-kappaB in breast cancer. Cancer Res. 2001;61:3810–8. [PubMed]
10. Hyder SM, Chiappetta C, Murthy L, Stancel GM. Selective inhibition of estrogen-regulated gene expression in vivo by the pure antiestrogen ICI 182,780. Cancer Res. 1997;57:2547–9. [PubMed]
11. Oliveira CA, et al. The antiestrogen ICI 182,780 decreases the expression of estrogen receptor-alpha but has no effect on estrogen receptor-beta and androgen receptor in rat efferent ductules. Reprod Biol Endocrinol. 2003;1:75. [PMC free article] [PubMed]
12. Kalaitzidis D, Gilmore TD. Transcription factor cross-talk: the estrogen receptor and NF-kappaB. Trends Endocrinol Metab. 2005;16:46–52. [PubMed]
13. Horwitz KB. Mechanisms of hormone resistance in breast cancer. Breast Cancer Res Treat. 1993;26:119–30. [PubMed]
14. Johnston SR, et al. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res. 1995;55:3331–8. [PubMed]
15. Rochefort H, et al. Estrogen receptor mediated inhibition of cancer cell invasion and motility: an overview. J Steroid Biochem Mol Biol. 1998;65:163–8. [PubMed]
16. Catz SD, Johnson JL. Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene. 2001;20:7342–51. [PubMed]
17. Xiang H, Wang J, Boxer LM. Role of the Cyclic AMP Response Element in the bcl-2 Promoter in the Regulation of Endogenous Bcl-2 Expression and Apoptosis in Murine B Cells. Mol Cell Biol. 2006;26:8599–606. [PMC free article] [PubMed]
18. Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer. 2006;6:449–58. [PubMed]
19. Burkly L, et al. Expression of relB is required for the development of thymic medulla and dendritic cells. Nature. 1995;373:531–6. [PubMed]
20. Stoffel A, Chaurushiya M, Singh B, Levine AJ. Activation of NF-kappaB and inhibition of p53-mediated apoptosis by API2/mucosa-associated lymphoid tissue 1 fusions promote oncogenesis. Proc Natl Acad Sci USA. 2004;101:9079–84. [PubMed]
21. Lessard L, Begin LR, Gleave ME, Mes-Masson AM, Saad F. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer. 2005;93:1019–23. [PMC free article] [PubMed]
22. Josson S, et al. RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells. Oncogene. 2005 [PMC free article] [PubMed]
23. Van Laere SJ, et al. Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding. Clin Cancer Res. 2006;12:3249–56. [PubMed]
24. Huber MA, et al. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest. 2004;114:569–81. [PMC free article] [PubMed]
25. Shin SR, Sanchez-Velar N, Sherr DH, Sonenshein GE. 7, 12-dimethylbenz(a)anthracene treatment of a c-rel mouse mammary tumor cell line induces epithelial to mesenchymal transition via activation of nuclear factor-kappaB. Cancer Res. 2006;66:2570–5. [PubMed]
26. Schmitt CA, et al. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell. 2002;1:289–98. [PubMed]
27. de Moissac D, Mustapha S, Greenberg AH, Kirshenbaum LA. Bcl-2 activates the transcription factor NFkappaB through the degradation of the cytoplasmic inhibitor IkappaBalpha. J Biol Chem. 1998;273:23946–51. [PubMed]
28. Fujita N, et al. MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell. 2003;113:207–19. [PubMed]
29. Guo S, Sonenshein GE. Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway. Mol Cell Biol. 2004;24:8681–90. [PMC free article] [PubMed]
30. Philips A, Chalbos D, Rochefort H. Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF7 breast cancer cells without affecting c-fos and c-jun synthesis. J Biol Chem. 1993;268:14103–8. [PubMed]
31. Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Sonenshein GE. Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells. Cancer Res. 2002;62:6770–8. [PubMed]
32. Min C, et al. The tumor suppressor activity of the lysyl oxidase pro-peptide reverses invasive phenotype of Her-2/neu driven breast cancer. Cancer Res. 2007 In press. [PubMed]
33. Schjerven H, Tran TN, Brandtzaeg P, Johansen FE. De novo synthesized RelB mediates TNF-induced up-regulation of the human polymeric Ig receptor. J Immunol. 2004;173:1849–57. [PubMed]
34. Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell. 1991;67:879–88. [PubMed]
35. Freund A, et al. Mechanisms underlying differential expression of interleukin-8 in breast cancer cells. Oncogene. 2004;23:6105–14. [PMC free article] [PubMed]